Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 2/20 | 0.37 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20437909 | 0.83 | NOTUM (0.58) | NOTUMKEAP1CYP19A1USP1WDR48 | |
| SCHEMBL24925228 | 0.81 | NOTUM (0.57) | NOTUMKEAP1CYP19A1USP1WDR48 | |
| SCHEMBL13122736 | 0.81 | NOTUM (0.63) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL30538076 | 0.80 | NOTUM (0.63) | NOTUMKEAP1CYP19A1KCNH2 | |
| SCHEMBL26918079 | 0.78 | NOTUM (0.57) | NOTUMKEAP1CYP19A1USP1WDR48 | |
| SCHEMBL12891749 | 0.78 | KDM5B (0.47) | NOTUMUSP1KDM5B | |
| SCHEMBL28267973 | 0.78 | NOTUM (0.56) | NOTUMKEAP1KCNH2 | |
| SCHEMBL16787394 | 0.76 | NOTUM (0.58) | NOTUMKEAP1CYP19A1KCNH2 | |
| SCHEMBL13735664 | 0.76 | NOTUM (0.58) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL26971181 | 0.75 | NOTUM (0.53) | NOTUMKEAP1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | PLEXXIKON INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703757-B2 | Compounds and methods for CDK8 modulation and indications therefor | CDK8, CDK7, CDK18 | NOTUM 1387/4885KEAP1 2819/4885CYP19A1 1060/4885 |
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | NOTUM 1387/4885KEAP1 2819/4885CYP19A1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.